CTOs on the Move

Talaris Therapeutics

www.talaristx.com

 
Talaris Therapeutics is a late-clinical stage biotechnology company based in Boston, MA and Louisville, KY. Talaris is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe auto-immune and immune-mediated disorders. The company was founded on technology discovered and developed by Dr. Suzanne Ildstad and operates its own cell processing facility in Louisville. Talaris is backed by leading life sciences investors Blackstone Life Sciences, Longitude Capital and Qiming Venture Partners USA.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.talaristx.com
  • 201 East Jefferson Street Suite 110B
    Louisville, KY USA 40202
  • Phone: 502.569.1059

Executives

Name Title Contact Details
Michael Zdanowski
Chief Technology Officer Profile
Eric Gornstein
Head of New Product Planning Profile
Carlos Yuraszeck
Senior Vice President of Technical Operations Profile

Funding

Talaris Therapeutics raised 4/18/2019 on 05/03/2019

Similar Companies

Strang Cancer Prevention Institute

Strang Cancer Prevention Institute is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Genentech

Genentech, Inc., is a biotechnology corporation which became a subsidiary of Roche in 2009.

Akriveia Therapeutics

`Akrevia` is derived from the Greek word for `precision`, which reflects our mission to precisely deliver the activity of potent, tailored immunotherapies exactly where it’s needed.

Pareto Biotechnologies

Pareto Biotechnologies has pioneered development of a revolutionary synthetic biology platform that produces naturally derived, high value “designer molecules.” Pareto’s technology is the result of over a decade of academic and private sector research and intellectual property focused on one particular polyketide pathway. Building on Dr. Joe Noel’s groundbreaking research at the Salk Institute, this pathway – previously dismissed as the “poor man’s pathway” – is the foundation of Pareto’s platform, capable of generating known products and novel molecules. In the near term, Pareto will introduce  “designer molecules” as cosmetics, flavors and fragrances including molecules with properties unlike anything previously experienced. In the long term, Pareto’s molecules will be designed to enhance nutraceuticals, pharmaceuticals, and industrial commodities. Pareto’s potential is limitless. Join us as we ignite a molecular revolution

Morphosys USA

Morphosys USA, Inc. is a Charlotte, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.